RAF inhibitor compounds and methods

Details RAF inhibitor compounds and methods RAF inhibitor compounds and methods

2006-02-02

2009-02-17

Saeed, Kamal A (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S406000

Reexamination Certificate

active

07491829

ABSTRACT:
Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

REFERENCES:
patent: 4000281 (1976-12-01), Beiler et al.
patent: 5356897 (1994-10-01), Oku et al.
patent: 5486534 (1996-01-01), Lee et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5843951 (1998-12-01), Inoue et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 6028072 (2000-02-01), Lee et al.
patent: 6423713 (2002-07-01), Anantanarayan et al.
patent: 6514977 (2003-02-01), Anantanarayan et al.
patent: 6525059 (2003-02-01), Anantanarayan et al.
patent: 6528509 (2003-03-01), Hale et al.
patent: 6750239 (2004-06-01), Hale et al.
patent: 6784195 (2004-08-01), Hale et al.
patent: 6849267 (2005-02-01), Bemis et al.
patent: 6949580 (2005-09-01), Hale et al.
patent: 2003/0078277 (2003-04-01), Hibi et al.
patent: 2003/0139452 (2003-07-01), Tang et al.
patent: 2003/0153588 (2003-08-01), Steadman et al.
patent: 2004/0038964 (2004-02-01), Dean et al.
patent: 2004/0048868 (2004-03-01), Edwards et al.
patent: 2004/0058918 (2004-03-01), Dominguez et al
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0116474 (2004-06-01), Munchhof et al.
patent: 2004/0127496 (2004-07-01), Dean et al.
patent: 2004/0147525 (2004-07-01), Kimura et al.
patent: 2004/0157838 (2004-08-01), Griffith
patent: 2004/0209883 (2004-10-01), Bamford et al.
patent: 2004/0235843 (2004-11-01), Bamford
patent: 2005/0026963 (2005-02-01), Cosford et al.
patent: 2005/0222230 (2005-10-01), Drysdale
patent: 2005/0245520 (2005-11-01), Dodic et al.
patent: 2006/0058329 (2006-03-01), Gellibert
patent: 1382603 (2004-01-01), None
patent: 1245283 (1971-09-01), None
patent: 05017470 (1993-01-01), None
patent: 05125079 (1993-05-01), None
patent: 10101671 (1998-04-01), None
patent: 10101672 (1998-04-01), None
patent: 2000153671 (2000-06-01), None
patent: WO 00/64422 (2000-11-01), None
patent: WO 02/072576 (2002-09-01), None
patent: WO 02/094808 (2002-11-01), None
patent: WO 02/094833 (2002-11-01), None
patent: WO 03/051358 (2003-06-01), None
patent: WO 03/055860 (2003-07-01), None
patent: WO 03/095455 (2003-11-01), None
patent: WO 2004/014900 (2004-02-01), None
patent: WO 2004/022055 (2004-03-01), None
patent: WO 2004/026302 (2004-04-01), None
patent: WO 2004/026871 (2004-04-01), None
patent: WO 2004/050659 (2004-06-01), None
patent: WO 2004/072033 (2004-08-01), None
Vippagunta, et al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Almansa et al., “Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo [1,5-a]pyrimidines”J Med Chem. 44(3):350-361 (Feb. 1, 2001).
Bellec et al., “Deaminative electrochemical reduction of pyrazolo [1,5-a]pyrimidine-7amines”Can.J. Chem. 59(19):2826-2832 (1981).
Comrie, A. M., “3,4,5-Triarylpyrazoles”Journal of the Chemical Society, Perkin Transactions 1(DatabaseCaplus [Online]; STN accession No. 1972:153662; Database accession No. 76:153662; RN: 36141-11-4; RN 36141-12-5), Letchworth:Gbchemical Society vol. 9-10:1193 (1972).
de Laszlo et al., “Pyrroles and other heterocycles as inhibitors of p38 kinase”Bioorg Med Chem Lett. 8(19):2689-2694 (Oct. 6, 1998).
Dombroski et al., “Benzimidazolone p38 inhibitors”Bioorg Med Chem Lett. 14:919-923 (Feb. 23, 2004).
Fray et al., “Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused[1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine” J Med Chem. 38(18):3524-3535 (Sep. 1, 1995).
Khilya et al., “Synthetic And Modified Isoflavonoids XV. Interaction of Synthetic Analogs of Isoflavones With Hydrazine Hydrate And Its Derivatives”Chemistry of Natural Compounds30(5):580-583 (1994).
Olivera et al., “A combination of tandem amine-exchange/heterocyclization and biaryl coupling reactions for the straightforward preparation of phenanthro[9,10-d]pyrazoles”J Org Chem. 65(21):7010-7019 (Oct. 20, 2000).
Penning et al., “3,4-Diarylpyrazoles: Potent and selective inhibitors of Cyclooxygenase-2”Bioorganic&medicinal chemistry letters7(16):2121-2124.
Sawyer et al., “Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain”J Med Chem. 46(19):3953-3956 (Sep. 11, 2003).
Complete International Search Report for International Patent Application No. PCT/US2006/003654, mailed Aug. 24, 2006.
Hansen, Joshua et al., “Potent and Selective Pyrazole-Based Inhibitors of B-Raf Kinase,”Bioorganic&Medicinal Chemistry Letter, pp. 4692-4695, 2008.

Affiliated with

Also associated with

Rating

RAF inhibitor compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RAF inhibitor compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RAF inhibitor compounds and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4126377